Effect of Screening on Ovarian Cancer Mortality
Author:
Top Cited Papers
Open Access
- 8 June 2011
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 305 (22) , 2295-2303
Abstract
In the United States, ovarian cancer is among the 5 leading causes of cancer death in women.1 The high case-fatality ratio of ovarian cancer may be attributed in part to its vague and nonspecific symptoms, which usually appear when the disease has reached an advanced stage. Ovarian cancer confined to the ovary has a 5-year survival of 92%. However, most women with ovarian cancer are diagnosed with advanced stage disease, which has a 5-year survival of only 30%.1 The recognition that early detection of ovarian cancer may have the potential to improve prognosis prompted the development of randomized controlled trials, including the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, to evaluate the efficacy of transvaginal ultrasound and serum cancer antigen 125 (CA-125) as screening tools to reduce ovarian cancer mortality.2-4Keywords
This publication has 18 references indexed in Scilit:
- A randomized study of screening for ovarian cancer: a multicenter study in JapanInternational Journal of Gynecological Cancer, 2008
- Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trialAmerican Journal of Obstetrics and Gynecology, 2005
- The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and statusControlled Clinical Trials, 2000
- Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trialControlled Clinical Trials, 2000
- Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trialControlled Clinical Trials, 2000
- Black participation in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trialControlled Clinical Trials, 2000
- Quality control of cancer screening examination procedures in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trialControlled Clinical Trials, 2000
- Death review process in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trialControlled Clinical Trials, 2000
- Recruitment strategies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: The first six yearsControlled Clinical Trials, 2000
- Screening for ovarian cancer: a pilot randomised controlled trialThe Lancet, 1999